Breaking News

Novo Nordisk Agrees to Acquire 3 Fill-Finish Sites from Novo Holdings

Expands manufacturing capacity to support Novo Nordisk’s supply of Semaglutide and other future assets.

Author Image

By: Charlie Sternberg

Associate Editor

Novo Nordisk has agreed to acquire three fill-finish sites from Novo Holdings A/S in connection with a transaction where Novo Holdings has agreed to acquire Catalent Inc., a global contract development and manufacturing organization headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.   The acquisition of the filling sites is aims to support Novo Nordisk’s supply of Semaglutide, which the company markets as Ozempic for type 2 diabetes and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters